Skip to content
10-Q

Quarterly Report

INMED PHARMACEUTICALS INC. INM

0001213900-26-014996

← back to feed
Filed
Feb 11, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · Feb 9, 2026 2.92M sh
Shares Diluted Q2 2026 · Dec 31, 2025 3.95M sh
Shares Diluted Q2 2026 · Dec 31, 2025 3.95M sh
Shares Diluted Q2 2026 · Dec 31, 2024 706.55K sh
Shares Diluted Q2 2026 · Dec 31, 2024 661.05K sh
Operating Cash Flow Q2 2026 · Dec 31, 2025 −$3.98M
Operating Cash Flow Q2 2026 · Dec 31, 2024 −$4.33M
Short Term Investments Q2 2026 · Dec 31, 2025 $42.68K
Short Term Investments Q2 2026 · Jun 30, 2025 $43.38K
Cash And Equivalents Q2 2026 · Dec 31, 2025 $6.95M
Cash And Equivalents Q2 2026 · Jun 30, 2025 $11.08M
Stockholders Equity Q2 2026 · Dec 31, 2025 $9.59M
Stockholders Equity Q2 2026 · Sep 30, 2025 $11.59M
Stockholders Equity Q2 2026 · Jun 30, 2025 $13.43M
Stockholders Equity Q2 2026 · Dec 31, 2024 $6.18M
Stockholders Equity Q2 2026 · Sep 30, 2024 $8.4M
Stockholders Equity Q2 2026 · Jun 30, 2024 $9.21M
Current Liabilities Q2 2026 · Dec 31, 2025 $1.48M
Current Liabilities Q2 2026 · Jun 30, 2025 $1.84M
Total Liabilities Q2 2026 · Dec 31, 2025 $1.6M
Total Liabilities Q2 2026 · Jun 30, 2025 $2.15M
Current Assets Q2 2026 · Dec 31, 2025 $8.79M
Current Assets Q2 2026 · Jun 30, 2025 $12.87M
Total Assets Q2 2026 · Dec 31, 2025 $11.19M
Total Assets Q2 2026 · Jun 30, 2025 $15.58M
Eps Diluted Q2 2026 · Dec 31, 2025 −$0.51
Eps Diluted Q2 2026 · Dec 31, 2025 −$0.95
Eps Diluted Q2 2026 · Dec 31, 2024 −$3.64
Eps Diluted Q2 2026 · Dec 31, 2024 −$6.43
Eps Basic Q2 2026 · Dec 31, 2025 −$0.51
Eps Basic Q2 2026 · Dec 31, 2025 −$0.95
Eps Basic Q2 2026 · Dec 31, 2024 −$3.64
Eps Basic Q2 2026 · Dec 31, 2024 −$6.43
Sga Expense Q2 2026 · Dec 31, 2025 $1.62M
Sga Expense Q2 2026 · Dec 31, 2025 $3.15M
Sga Expense restated Q2 2026 · Dec 31, 2024 $1.72M
Sga Expense restated Q2 2026 · Dec 31, 2024 $3.21M
Rd Expense Q2 2026 · Dec 31, 2025 $630.64K
Rd Expense Q2 2026 · Dec 31, 2025 $1.21M
Rd Expense restated Q2 2026 · Dec 31, 2024 $895.18K
Rd Expense restated Q2 2026 · Dec 31, 2024 $1.6M
Net Income Q2 2026 · Dec 31, 2025 −$2.03M
Net Income Q2 2026 · Dec 31, 2025 −$3.76M
Net Income Q2 2026 · Sep 30, 2025 −$1.73M
Net Income Q2 2026 · Dec 31, 2024 −$2.58M
Net Income Q2 2026 · Dec 31, 2024 −$4.25M
Net Income Q2 2026 · Sep 30, 2024 −$1.68M
Gross Profit Q2 2026 · Dec 31, 2025 $184.19K
Gross Profit Q2 2026 · Dec 31, 2025 $587.35K
Gross Profit Q2 2026 · Dec 31, 2024 $460.89K
Gross Profit Q2 2026 · Dec 31, 2024 $954.31K
Cost Of Revenue Q2 2026 · Dec 31, 2025 $635.99K
Cost Of Revenue Q2 2026 · Dec 31, 2025 $1.35M
Cost Of Revenue Q2 2026 · Dec 31, 2024 $650.81K
Cost Of Revenue Q2 2026 · Dec 31, 2024 $1.42M